Streptokinase Injections Dealers

• Country of Origin: India
• Composition: Streptokinase (1500000IU)
• Treatment: Heart Attack
• Packaging Type: 10x1 Vial
• Brand Name: LCIKINASE
• Prescription/Non prescription: Injection
• Manufacturer: Manufacturer

• Brand Name: Kabikinase, Streptase
• Usage: Streptokinase 1500mg Injection is a medicine used to break down harmful blood clots that have formed in the blood vessels.
• Name: Streptokinase Injection
• MOQ: 5

The raw materials that are used for the production of our finished products are acquired in minimally processed or unprocessed states; these are free from impurities as well. In order to keep the products in safe condition during handling, warehousing and transit, we make use of only premium packaging materials. Moreover, our skilled personnel are employed for carrying out the task of packing.Uses of Stpase :Acute myocardial infarction, Arterial thrombosis, Deep vein thrombosis, Desloughing wounds, Duodenal ulcer and gastric ulcer, Myocardial infarction, Prophylaxis of NSAID-associated gastric or duodenal ulcer, Pulmonary embolism, Thrombosis.Plasminogen is an inactive molecule that becomes activated to plasmin when the Arg/Val bond is cleaved. Plasmin breaks down fibrin clots created by the blood clotting cascade. Streptokinase forms a highly specific 1:1 enzymatic complex with plasminogen which converts inactive plasminogen molecules into active plasmin.Plasmin degrades fibrin clots as well as fibrinogen and other plasma proteins. This in turn leads to the degradation of blood clots.

• Brand Name: GJ
• Packaging Size: Single vial
• Dose: 1500000 IU
• ]Storage: Store in cool and dry place
• Best Before: 6 months from Manufacture date
• Form Of Medicine: Injection

Description:Streptase, Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. It is supplied as a lyophilized white powder containing 25 mg cross-linked gelatin polypeptides, 25 mg sodium L-glutamate, sodium hydroxide to adjust pH, and 100 mg Albumin (Human) per vial or infusion bottle as stabilizers. The preparation contains no preservatives and is intended for intravenous and intracoronary administration. Indications:Acute Evolving Transmural Myocardial Infarction: Streptase, Streptokinase, is indicated for use in the management of acute myocardial infarction (AMI) in adults, for the lysis of intracoronary thrombi, the improvement of ventricular function, and the reduction of mortality associated with AMI, when administered by either the intravenous or the intracoronary route, as well as for the reduction of infarct size and congestive heart failure associated with AMI when administered by the intravenous route. Earlier administration of Streptokinase is correlated with greater clinical benefit. (See CLINICAL PHARMACOLOGY.) Pulmonary Embolism:   Streptase, Streptokinase, is indicated for the lysis of objectively diagnosed (angiography or lung scan) pulmonary emboli, involving obstruction of blood flow to a lobe or multiple segments, with or without unstable hemodynamics. Deep Vein Thrombosis:   Streptase, Streptokinase, is indicated for the lysis of objectively diagnosed (preferably ascending venography), acute, extensive thrombi of the deep veins such as those involving the popliteal and more proximal vessels. Arterial Thrombosis or Embolism:   Streptase, Streptokinase, is indicated for the lysis of acute arterial thrombi and emboli. Streptokinase is not indicated for arterial emboli originating from the left side of the heart due to the risk of new embolic phenomena such as cerebral embolism. Occlusion of Arteriovenous Cannulae:   Streptase, Streptokinase, is indicated as an alternative to surgical revision for clearing totally or partially occluded arteriovenous cannulae when acceptable flow cannot be achieved. Dosage and Administration : Acute Evolving Transmural Myocardial Infarction:   Administer Streptokinase as soon as possible after onset of symptoms. The greatest benefit in mortality reduction was observed when Streptokinase was administered within four hours, but statistically significant benefit has been reported up to 24 hours (see CLINICAL PHARMACOLOGY ). Warnings:Bleeding:   Following intravenous high-dose brief-duration Streptokinase therapy in acute myocardial infarction, severe bleeding complications requiring transfusion are extremely rare (0.3-0.5%), and combined therapy with low dose aspirin does not appear to increase the risk of major bleeding. The addition of aspirin to Streptokinase may cause a slight increase in the risk of minor bleeding (3.1% without aspirin vs. 3.9% with) (2) . Streptokinase will cause lysis of hemostatic fibrin deposits such as those occurring at sites of needle punctures, particularly when infused over several hours, and bleeding may occur from such sites. In order to minimize the risk of bleeding during treatment with Streptokinase, venipunctures and physical handling of the patient should be performed carefully and as infrequently as possible, and intramuscular injections must be avoided. Should an arterial puncture be necessary during intravenous therapy, upper extremity vessels are preferable. Pressure should be applied for at least 30 minutes, a pressure dressing applied, and the puncture site checked frequently for evidence of bleeding. In the following conditions the risks of therapy may be increased and should be weighed against the anticipated benefits. Recent (within 10 days) major surgery, obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels Recent (within 10 days) serious gastrointestinal bleeding Recent (within 10 days) trauma including cardiopulmonary resuscitation Hypertension: systolic BP >180 mm Hg and/or diastolic BP >110 mm Hg High likelihood of left heart thrombus, e.g., mitral stenosis with atrial fibrillation Subacute bacterial endocarditis Hemostatic defects including those secondary to severe hepatic or renal disease Pregnancy Age >75 years Cerebrovascular disease

• Form: Tablets / Liquid / Capsules / Powder
• Packaging Type: Plastic Bottle
• Usage: Clinical, hospital etc.
• CATEGORY: Thrombolytic
• Dosage: 5mg
• Grade Standard: Medicine Grade
• Storage: Cool and Dry Place
• Storage: Cool and Dry Place

Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU is used in Acute Evolving Transmural Myocardial Infarction:  Streptokinase, is indicated for use in the management of acute myocardial infarction (AMI) in adults, for the iysis of intracoronary thrombi, the improvement of ventricular function, and the reduction of mortality associated with AMI, when administered by either the intravenous or the intracoronary route, as well as for the reduction of infarct size and congestive heart failure associated with AMI when administered by the intravenous route. Pulmonary Embolism: Streptokinase, is indicated for the lysis of objectively diagnosed (angiography or lung scan) pulmonary emboli, involving obstruction of blood flow to a lobe or multiple segments, with or without unstable hemodynamics. Deep Vein Thrombosis: Streptokinase, is indicated for the lysis of objectively diagnosed (preferably ascending venography), acute, extensive thrombi of the deep veins such as those involving the popliteal and more proximal vessels. Arterial Thrombosis or Embolism: Streptokinase, is indicated for the lysis of acute arterial thrombi and emboli. Streptokinase is not indicated for arterial emboli originating from the left side of the heart due to the risk of new embolic phenomena such as cerebral embolism. Occlusion of Arteriovenous Cannulae: Streptokinase, is indicated as an alternative to surgical revision for clearing totally or partially occluded arteriovenous cannulae when acceptable flow cannot be achieved. There are many generic manufacturers in India who manufacture Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU including Zydus Cadila Healthcare ,Biocon(India)Ltd and Piramal Healthcare  etc. 3s corporation is Supplier,Exporter ,Wholesaler  for Streptokinase  Injection 2.5 / 5 / 7.5 / 15 Lac IU in India.     ADDITIONAL INFORMATION Administer Streptokinase as soon as possible after onset of symptoms. The greatest benefit in mortality reduction was observed when Streptokinase was administered within four hours, but statistically significant benefit has been reported up to 24 hours.   SIDE EFFECTS Bleeding:   The reported incidence of bleeding (major or minor) has varied widely depending on the indication, dose, route and duration of administration, and concomitant therapy. Minor bleeding can be anticipated mainly at invaded or disturbed sites. If such bleeding occurs, local measures should be taken to control the bleeding. Severe internal bleeding involving gastrointestinal (including hepatic bleeding), genitourinary, retroperitoneal, or intracerebral sites has occurred and has resulted in fatalities. In the treatment of acute myocardial infarction with intravenous Streptokinase, the GISSI and ISIS-2 studies reported a rate of major bleeding (requiring transfusion) of 0.3-0.5%. However, rates as high as 16% have been reported in studies which required administration of anticoagulants and invasive procedures. Allergic Reactions:  Fever and shivering, occurring in 1-4% of patients(1,2) , are the most commonly reported allergic reactions with intravenous use of Streptase, Streptokinase, in acute myocardial infarction. Anaphylactic and anaphylactoid reactions ranging in severity from minor breathing difficulty to bronchospasm, periorbital swelling or angioneurotic edema have been observed rarely. Other milder allergic effects such as urticaria, itching, flushing, nausea, headache and musculoskeletal pain have also been observed, as have delayed hypersensitivity reactions such as vasculitis and interstitial nephritis.  Respiratory:   There have been reports of respiratory depression in patients receiving Streptokinase. In some cases, it was not possible to determine whether the respiratory depression was associated with Streptokinase or was a symptom of the underlying process. If respiratory depression is associated with Streptokinase, the occurrence is believed to be rare. Other Adverse Reactions:   Transient elevations of serum transaminases have been observed. The source of these enzyme rises and their clinical significance is not fully understood.

• Packaging Type: Vial
• Composition: Streptokinase Injection IP
• Dose/Strength: 15 Lac i.u/vial
• Manufactured By: Samarth Life Sciences Pvt Ltd
• Application: Hospital
• Storage Instruction: Store in a refrigerator (2 - 8 DegreeC). Do not freeze.

• Packaging Type: Box
• Packaging Size: 10x1 Vial
• Country of Origin: India
• Form: Injection
• Manufactured By: Abbott
• Generic Name: Icikinase
• Strength :: 1500000 IU

• Brand Name: Icikinase
• Packaging Size: 5ml (Vial)
• Best Before: 18-36 Months From the date of Manufacture
• Salt Composition: Recombinant Streptokinase (1500000IU)
• Directions For Use: Use as directed by your healthcare professional.
• Dosage: The dose and duration should be followed as prescribed by the physician.